other material
confidence high
sentiment positive
materiality 0.85
Altimmune reports positive 24-week pemvidutide NAFLD trial: >75% liver fat reduction, 7.2% weight loss at 1.8 mg
Altimmune, Inc.
- At 1.8 mg dose, mean relative liver fat reduction 75.2%; 53.8% achieved normalization (≤5% LFC).
- Mean weight loss of 7.2% (placebo-adjusted 6.0%) in non-diabetic subjects at 1.8 mg dose.
- Significant ALT declines: ≥17 IU/L reduction in subjects with baseline ALT ≥30 IU/L across all doses.
- cT1 response (≥80 ms reduction) achieved in 75% (1.8 mg) and 100% (2.4 mg) of evaluated subjects.
- Pemvidutide well tolerated; 3 serious/severe AEs unrelated to drug; no significant ALT elevations.